We read with interest the paper by Wright TE et al.
Prenatal tobacco exposure has been usually assessed using selfreported maternal questionnaire. Difficulties in differentiating passive tobacco exposure from active smoking (among there reluctant to admit active smoking or unconscious of passive exposure) have prompted the use of specific biomarkers to prevent bias in self-reported questionnaires. 3, 4 Nicotine and its main metabolite (cotinine) have been used as biomarkers for second-hand smoke in conventional (blood and urine) and non-conventional matrices (saliva, meconium and hair). 5 Cotinine presents a longer biological half-life than nicotine, and it is considered the best biochemical marker to differentiate between active and passive tobacco exposure. Moreover, the levels of cotinine have been found to be directly related with daily cigarette consumption. 6 We believe that the accurate assessment of fetal exposure to smoking through the objective measure of a biomarker could be of major importance in cohort studies, in which the ultimate goal is monitoring passive exposure to tobacco smoke and the investigation of the effects of prenatal and postnatal environmental exposures to pollutants, including tobacco smoke. Cord serum cotinine appeared to be an adequate biomarker due to its ability to be associated with levels of active smoking, levels of passive maternal exposure to smoking, and to neonatal effects such as birth weight. Cord serum cotinine is able to discriminate active smoking from exposure to environmental tobacco smoke and exposure from non-exposure. Finally, the ease of collection and processing of cord blood advocate for the extension of the use of cord serum cotinine as a biomarker of prenatal exposure to smoking. 2 Cotinine cord blood is the most sensitive and less invasive measure of prenatal second-hand smoke in newborns and usually has a good correlation with self-reported smoking parents. 2, 7, 8 
